Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AP Loves The Thrill Of The Hunt Way More Than Kill-er Data

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Apr 07, 2023 7:17pm

127 Views

Post# 35384956

RE:RE:RE:RE:AP Loves The Thrill Of The Hunt Way More Than Kill-er Data

Names Names Names. That's all you've. Meanwhile, you want someone to play your sily little gsme of hide gthe ball. You go jump through hoops Care Bear to all get to those proclaimed success rates that show a 60% chance of success. Stop following yojur Riverdance buddy across the floor before you slip and fall again. Do us all a favor. Shuuu The LL Up util you can figure out how to cut and paste the page you claim exists. Real Due Diligence. Go find some.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments